Adcendo and MSD Expand KEYTRUDA Cancer Trial
COPENHAGEN, Denmark, May 26, 2026 Adcendo ApS has announced a new clinical collaboration and supply agreement with MSD (Merck...
antibody drug conjugate
Advertisement
Merck’s KEYTRUDA and Padcev Combination Shows Strong Survival Benefit Ahead of EU Approval
RAHWAY, New Jersey, May 24, 2026 Merck announced that the European Medicines Agency’s Committee for Medicinal Products for Human...
AstraZeneca and Daiichi Sankyo Advance Enhertu in Tumour-Agnostic Oncology
Cambridge, United Kingdom – May 22, 2026 AstraZeneca and Daiichi Sankyo announced that the European Medicines Agency’s Committee for...
BioNTech Highlights Late-Stage Cancer Pipeline at ASCO
MAINZ, Germany, May 22, 2026 BioNTech announced new clinical data presentations and pipeline updates from its expanding late-stage oncology...
Astellas’ PADCEV Combo Wins CHMP Support in MIBC
Tokyo, Japan – May 22, 2026 Astellas Pharma Inc. announced that the European Medicines Agency’s Committee for Medicinal Products...
Advertisements
Gilead’s Trodelvy Wins CHMP Support in 1L TNBC
FOSTER CITY, Calif., May 25, 2026 Gilead Sciences announced that the European Medicines Agency’s Committee for Medicinal Products for...
Datroway by AstraZeneca Approved as First TROP2 ADC for TNBC
Cambridge, United Kingdom – May 22, 2026 AstraZeneca and Daiichi Sankyo announced that the U.S. Food and Drug Administration...
Merck Sac-TMT Trial Shows Survival Benefit in Cancer
Rahway, N.J., USA – May 18, 2026 Merck announced that its pivotal Phase 3 TroFuse-005 clinical trial evaluating sacituzumab...
Mabwell Showcases Strong 9MW2821 Bladder Cancer Data at ASCO 2026
SHANGHAI, China, 22 May 2026 Mabwell announced that new clinical data for its investigational Nectin-4-targeting antibody-drug conjugate (ADC) 9MW2821...
Kelun-Biotech Gains China IND Clearance for SKB118
CHENGDU, China, May 12, 2026 Kelun-Biotech announced that China’s Center for Drug Evaluation (CDE) under the National Medical Products...
Advertisement
